Anticompetitive Drug Rebates May Need FTC Rulemaking For Timely Reform, Commissioners Say

‘Rebate walls’ report heads to US Congress, but Democratic commissioners suggest FTC’s typical approach to curtailing such practices is too time consuming.

FTC Statue Of 'Man Controlling Trade:' A Model For More Vigorous Enforcement? • Source: Alamy

The Federal Trade Commission should use its rulemaking authority to address anticompetitive pharmaceutical industry practices like “rebate walls,” FTC Acting Chair Rebecca Slaughter and fellow Democratic commissioner Rohit Chopra urged in statements accompanying a commission report on rebate walls.

The FTC report, which was sent to Congress on 28 May, was requested by the US House as part...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Legal & IP

More from Pink Sheet